- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05267873
Combining Data Sources to Identify Effect Moderation for Personalized Mental Health
April 9, 2024 updated by: Johns Hopkins Bloomberg School of Public Health
This work will extend and apply methods for modeling heterogeneous treatment effects when multiple studies are available, with a particular focus on the complexities in mental health research.
The methods will be illustrated in examples estimating the effects of medical treatments for major depressive disorder (duloxetine and vortioxetine) using 4 randomized controlled trials (available in the Vivli trials resource) and non-experimental data from the Duke University Health System electronic health record and the Johns Hopkins Health System electronic health record systems.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Estimated)
14146
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21205
- Johns Hopkins Bloomberg School of Public Health
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
N/A
Sampling Method
Non-Probability Sample
Study Population
Patients who received Duloxetine or Vortioxetine
Description
Duke University Health System Electronic Health Record (EHR) System and Johns Hopkins Health System EHR System
Inclusion criteria:
- All patients prescribed any Duloxetine or Vortioxetine in the health systems between 01/01/2015 - 12/31/2021.
- AND from patients with at least 1-year historical EHR data (burn-in period) without prescribing any of the two medications. During the burn-in period, patients should have at least one encounter in the system, and with no encounters during that time frame when they were prescribed Duloxetine or Vortioxetine.
- AND patients age 18-65 years old at baseline.
Exclusion criteria:
- Patients prescribed both Duloxetine and Vortioxetine at baseline would be removed.
4 randomized controlled trials (RCTs)
Inclusion criteria:
- Male or female
- Age 18 years or older
- Major depressive episode according to Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text Revision (DSM-IV-TR) classification code 296.3x
- Montgomery-Asberg Depression Rating Scale (MADRS) total score ≥ 26
- Clinical Global Impression - Severity (CGI-S) scale score ≥ 4
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Duke Health System Electronic Health Record
Patients who received Duloxetine or Vortioxetine
|
Medications for major depressive disorder
|
Johns Hopkins Health System Electronic Health Record
Patients who received Duloxetine or Vortioxetine
|
Medications for major depressive disorder
|
Randomized Controlled Trial 1 (NCT01153009)
Patients who received Duloxetine or Vortioxetine
|
Medications for major depressive disorder
|
Randomized Controlled Trial 2 (NCT01140906)
Patients who received Duloxetine or Vortioxetine
|
Medications for major depressive disorder
|
Randomized Controlled Trial 3 (NCT00672620)
Patients who received Duloxetine or Vortioxetine
|
Medications for major depressive disorder
|
Randomized Controlled Trial 4 (NCT00635219)
Patients who received Duloxetine or Vortioxetine
|
Medications for major depressive disorder
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
9-question Patient Health Questionnaire (PHQ-9) or PHQ-2 scores
Time Frame: 6 months
|
Higher score indicates greater severity of major depressive disorder.
|
6 months
|
9-question Patient Health Questionnaire (PHQ-9) or PHQ-2 scores
Time Frame: 1 year
|
Higher score indicates greater severity of major depressive disorder.
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Emergency room visits or inpatient admissions with diagnosis of depression or suicidality
Time Frame: 6 months
|
A binary outcome equals to 'Yes' if the patient ever had any emergency department or inpatient hospital admission encounter with depression or suicidality International Classification of Diseases (ICD) codes, otherwise equals to "No".
|
6 months
|
Emergency room visits or inpatient admissions with diagnosis of depression or suicidality
Time Frame: 1 year
|
A binary outcome equals to 'Yes' if the patient ever had any emergency department or inpatient hospital admission encounter with depression or suicidality International Classification of Diseases (ICD) codes, otherwise equals to "No".
|
1 year
|
Emergency room visits or inpatient admissions for any reason
Time Frame: 6 months
|
A binary outcome equals to 'Yes' if the patient ever had any emergency department or inpatient hospital admission encounter after the prescription, otherwise equals to "No".
|
6 months
|
Emergency room visits or inpatient admissions for any reason
Time Frame: 1 year
|
A binary outcome equals to 'Yes' if the patient ever had any emergency department or inpatient hospital admission encounter after the prescription, otherwise equals to "No".
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Elizabeth Stuart, PhD, Johns Hopkins Bloomberg School of Public Health
- Principal Investigator: Hwanhee Hong, PhD, Department of Biostatistics & Bioinformatics, Duke University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2015
Primary Completion (Actual)
December 31, 2021
Study Completion (Estimated)
December 31, 2024
Study Registration Dates
First Submitted
February 20, 2022
First Submitted That Met QC Criteria
March 2, 2022
First Posted (Actual)
March 4, 2022
Study Record Updates
Last Update Posted (Actual)
April 11, 2024
Last Update Submitted That Met QC Criteria
April 9, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Mood Disorders
- Depressive Disorder
- Depressive Disorder, Major
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Serotonin Agents
- Antidepressive Agents
- Dopamine Agents
- Serotonin 5-HT1 Receptor Agonists
- Serotonin Receptor Agonists
- Serotonin Antagonists
- Anti-Anxiety Agents
- Serotonin and Noradrenaline Reuptake Inhibitors
- Serotonin 5-HT3 Receptor Antagonists
- Selective Serotonin Reuptake Inhibitors
- Duloxetine Hydrochloride
- Vortioxetine
Other Study ID Numbers
- 17538
- IRB00017538 (Other Identifier: JHSPH IRB)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depressive Disorder, Major
-
Shalvata Mental Health CenterUnknownMAjor Depressive DisorderIsrael
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDDIndia
-
Gangnam Severance HospitalCompletedMajor Depressive Disorder(MDD)Korea, Republic of
-
University College, LondonCompletedUnipolar Major Depressive DisorderUnited Kingdom
-
Fundació Institut de Recerca de l'Hospital de la...Fondo de Investigacion SanitariaUnknown
-
York UniversityCentre for Addiction and Mental HealthSuspendedDisorder, Major DepressiveCanada
-
AccexibleRecruitingMajor Depressive Disorder (MDD)Spain
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Not yet recruitingMajor Depressive Disorder (MDD)
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.RecruitingMajor Depressive Disorder (MDD)China
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedSingle Dose Oral Bioequivalence Study of Vortioxetine Hemihydrobromide Orally Disintegrating TabletsMajor Depressive Disorder (MDD)India
Clinical Trials on Duloxetine, Vortioxetine
-
H. Lundbeck A/SCompleted
-
H. Lundbeck A/SCompleted
-
TakedaCompletedDepressive Disorder, MajorUnited States, Ukraine, Germany, Poland, Bulgaria, Finland, Russian Federation
-
H. Lundbeck A/SCompleted
-
H. Lundbeck A/SCompleted
-
Shanghai Mental Health CenterJiangsu Nhwa Pharmaceutical Co., Ltd.Completed
-
H. Lundbeck A/SCompletedPharmacokineticsChina
-
Boehringer IngelheimCompletedDiabetic Neuropathies | Depressive Disorder, MajorGermany
-
H. Lundbeck A/SCompleted
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDDIndia